Capricor Therapeutics Shares Decline Despite Positive Analyst Ratings

Capricor Therapeutics shares are trading lower despite Maxim maintaining a Buy rating and raising the price target to $50, H.C. Wainwright raising the price target to $60, and Alliance Global raising the price target to $48 following positive trial data. The decline may reflect broader market conditions or investor skepticism.